tariquidar has been researched along with Breast Cancer in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Callaghan, R; Martin, C; Walker, J | 1 |
| Charlton, PA; Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, SJ; Mills, L; Norris, D; Prin, A; Sharma, S; Whitehouse, PA | 1 |
| Müller, H; Pick, A; Wiese, M | 1 |
| Bernhardt, G; Buschauer, A; Egger, M; Fricker, G; König, B; Kühnle, M; Mahringer, A; Müller, C | 1 |
| Bönisch, H; Haenisch, B; Mayer, R; Müller, CE; Müller, H; Pajeva, IK; Pick, A; Weigt, M; Wiese, M | 1 |
| Bauer, S; Bernhardt, G; Bürger, K; Buschauer, A; Höcherl, P; König, B; Kühnle, M; Puentes, CO | 1 |
| Haag, R; Li, W; Li, Y; Pan, Y; Parshad, B; Zhou, S | 1 |
| Karbaum, M; Marighetti, F; Steggemann, K; Wiese, M | 1 |
| Borst, P; Iyer, JK; Jonkers, J; Kersbergen, A; Nygren, AO; Pajic, M; Rottenberg, S; van der Burg, E | 1 |
| Gao, M; Hutchins, GD; Luo, MB; Miller, KD; Wang, M; Zheng, DX; Zheng, QH | 1 |
| Klinkhammer, W; Pick, A; Wiese, M | 1 |
| Bankstahl, JP; Bankstahl, M; Erker, T; Kuntner, C; Langer, O; Löscher, W; Mairinger, S; Müller, M; Sauberer, M; Stanek, J; Strommer, S; Wacheck, V; Wanek, T | 1 |
| Ambudkar, SV; Gottesman, MM; Hall, MD; Halldin, C; Innis, RB; Kannan, P; Pike, VW; Shukla, S; Telu, S | 1 |
| Hanl, M; Marighetti, F; Steggemann, K; Wiese, M | 1 |
| Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K | 1 |
| Blumenschein, G; Boniface, G; Booser, D; Fleming, DR; Hortobagyi, GN; Ibrahim, N; Pusztai, L; Rivera, E; Rouzier, R; Symmans, FW; Theriault, R; Wagner, P; Wong, F | 1 |
| Azzariti, A; Berardi, F; Cantore, M; Colabufo, NA; Contino, M; Inglese, C; Niso, M; Paradiso, A; Perrone, MG; Perrone, R; Porcelli, L; Simone, GM | 1 |
1 trial(s) available for tariquidar and Breast Cancer
| Article | Year |
|---|---|
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Quinolines; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed | 2005 |
16 other study(ies) available for tariquidar and Breast Cancer
| Article | Year |
|---|---|
Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Division; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Quinolines; Spheroids, Cellular; Tumor Cells, Cultured; Vinblastine | 2004 |
Ex vivo reversal of chemoresistance by tariquidar (XR9576).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Quinolines; Skin Neoplasms; Tumor Cells, Cultured | 2004 |
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Models, Molecular; Molecular Structure; Neoplasm Proteins; Phthalic Acids; Quantitative Structure-Activity Relationship; Quinolines; Reproducibility of Results; Stereoisomerism; Time Factors; Tumor Cells, Cultured | 2008 |
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Female; Humans; Inhibitory Concentration 50; Multidrug Resistance-Associated Protein 2; Neoplasm Proteins; Quinolines; Structure-Activity Relationship | 2009 |
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Hydrogen Bonding; Models, Molecular; Neoplasm Proteins; Quantitative Structure-Activity Relationship | 2011 |
Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Combinatorial Chemistry Techniques; Dose-Response Relationship, Drug; Female; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasm Proteins; Protein Transport; Quinolines | 2011 |
Novel dendritic polyglycerol-conjugated, mesoporous silica-based targeting nanocarriers for co-delivery of doxorubicin and tariquidar to overcome multidrug resistance in breast cancer stem cells.
Topics: Breast Neoplasms; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Glycerol; Humans; MCF-7 Cells; Nanoparticles; Neoplastic Stem Cells; Polymers; Quinolines; Silicon Dioxide | 2021 |
Scaffold identification of a new class of potent and selective BCRP inhibitors.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Quinolines | 2015 |
Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Breast Neoplasms; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, BRCA1; Genes, p53; Humans; Mice; Mice, Knockout; Quinolines; Tumor Burden; Up-Regulation | 2009 |
Synthesis of carbon-11-labeled tariquidar derivatives as new PET agents for imaging of breast cancer resistance protein (ABCG2).
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carbon Radioisotopes; Female; Humans; Isotope Labeling; Neoplasm Proteins; Positron-Emission Tomography; Quinolines | 2010 |
Specific inhibitors of the breast cancer resistance protein (BCRP).
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Chlorophyll; Diketopiperazines; Drug Resistance, Multiple; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Imatinib Mesylate; Indoles; Neoplasm Proteins; Novobiocin; Piperazines; Pyrimidines; Quinolines; Structure-Activity Relationship | 2010 |
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Breast Neoplasms; Carbon Radioisotopes; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gene Expression Regulation, Neoplastic; Mice; Phenotype; Positron-Emission Tomography; Quinolines; Tetrahydroisoquinolines; Verapamil | 2012 |
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Female; HEK293 Cells; Humans; Neoplasm Proteins; Quinolines; Substrate Specificity | 2011 |
Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mitoxantrone; Neoplasm Proteins; Quantitative Structure-Activity Relationship; Quinolines | 2013 |
Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan | 2004 |
Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives.
Topics: Acridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Female; Humans; Isoquinolines; Ligands; Quinolines; Structure-Activity Relationship; Tetrahydroisoquinolines | 2008 |